Completed OBSERVATIONAL NCT01401478

Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation

Prospective, Open-label, Multicenter Effectiveness and Safety Observational Study of Zemplar in Patients With Stage 5 Chronic Kidney Disease and Hyperparathyroidism on Hemodialysis in the Russian Federation

Sponsor: AbbVie (prior sponsor, Abbott)

Conditions Secondary Hyperparathyroidism

Updated 7 times since 2017 Last updated: Feb 28, 2014 Started: Jul 31, 2011 Primary completion: Jan 31, 2013 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Secondary Hyperparathyroidism, this trial is completed. The trial is conducted by AbbVie (prior sponsor, Abbott) and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie (prior sponsor, Abbott)
Almedis

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Al'met'yevsk, Russia , Cheboksary, Russia , Chelyabinsk, Russia , Iakutsk, Russia , Irkutsk, Russia , Kazan', Russia , Moscow, Russia , Novosibirsk, Russia , Orenburg, Russia , Saint Petersburg, Russia and 2 more locations